Clinical trial · Interventional
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
NCT02862613CI-TRIAL-00023756unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Liver Cancer | Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
| Precision Cells | — | UNRESOLVED | — |
| Transcatheter Arterial Chemoembolization | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Precision Cells | Biological | — | UNRESOLVED |
| TACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Precision Cells
- description
- Precision Cells combined with Transcatheter Arterial Chemoembolization: Transcatheter Arterial Chemoembolization: patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment
- interventionNames
- Procedure: TACE
- Biological: Precision Cells
- type
- ACTIVE_COMPARATOR
- label
- Transcatheter Arterial Chemoembolization
- description
- patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
- interventionNames
- Procedure: TACE
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18\~65 years old, male or female; * Life expectancy≥6 months; * ECOG score: 0-3; * Advanced Malignancies (lung cancer, gastric cancer) were diagnosed by pathological or clinical physicians,and Diagnosis of hepatocellular carcinoma (HCC), surgery can not be performed but TACE treatment can be carried out; * Enough venous channel, no other contraindications to the separation and collection of white blood cells; * Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L, hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level; * Signed informed consent; * Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. Exclusion Criteria: * Expected Overall survival \< 3 months; * The tumor size or quantity is not suitable for interventional treatment or portal vein tumor thrombus; * Liver function is Childs Pugh C; * Had received TACE therapy previously or in radiotherapy at present,or taking Sola Feeney; * Other serious diseases:the heart,lung, kidney, digestive, nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc; * Unable or unwilling to provide informed consent, or fail to comply with the test requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.